Foto del docente

Alessandro Baldi Antognini

Full Professor

Department of Statistical Sciences "Paolo Fortunati"

Academic discipline: SECS-S/01 Statistics

Research

Keywords: design of experiments randomization Markov chains adaptive designs asymptotic inference

1.  Adaptive experiments for comparative trials. In general, sequential designs are stochastic processes, where the dependence structure changes on the basis of the information that will be used in the future assignments. In this context we have analyzed the properties of sequential designs (asymptotic optimality, speed of convergence, correct inferential approach ...) both for response-adaptive and design-adaptive procedures. Furthermore, we have introduced some new proposals of restricted randomization mechanism, based on Polya urn models and suitable Markov chains, for balancing the sequential allocation of two treatments in clinical trials. 

2.      Dose-escalation experiments. Traditionally, dose-escalation experiments are binary clinical trials designed for the estimation of the dose with a prefixed probability of toxicity. In this setting we have proposed some extensions of the classical Up&Down procedures (assuming that the dose-allocation process is random and subjects are treated in groups), particularly useful  even for non-dichotomous responses.  

3.      Optimal design theory for non-linear problems. Response-adaptive experiments represents a natural solution for local optimality problems, which occur very often in the so-called non-linear problems. The research activity was focused on asymptotic inference and asymptotic optimality for sequential procedures. Furthermore, the optimal design theory was applied to  random fields regression models, namely regressive models with correlated observations, very popular in the analysis of Computer Experiments.

4.      Statistical applications to clinical trials, jointly with the Neurological Unit of the University of Bologna (Azienda Ospedaliera di Bologna, Policlinico S. Orsola–Malpigli).

 

Latest news

At the moment no news are available.